Skip to main content
. Author manuscript; available in PMC: 2020 Jun 23.
Published in final edited form as: Adv Exp Med Biol. 2017;962:435–448. doi: 10.1007/978-981-10-3233-2_26

Figure 1-2.

Figure 1-2.

RUNX2 manifests its oncogenic activity through upregulation of a soluble form of E-Cadherin (sE-Cad) that inactivates the Hippo tumor suppressor pathway. Conversely, fulllength membrane bound E-Cadherin positively regulates the Hippo signaling pathway to keep RUNX2 oncogenic function in check.